Factors linked to severe dermatomyositis in Caribbean adults
Severity Factors of Dermatomyositis in the Caribbean Population - DM-ANTILLES
See if specific clinical, demographic, and ancestral factors are linked to more severe dermatomyositis in adults of Caribbean ancestry living in Guadeloupe.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de la Guadeloupe Academic / other |
| Locations | 1 site (Pointe-à-Pitre) |
| Trial ID | NCT07265999 on ClinicalTrials.gov |
What this trial studies
This observational project will identify new cases of dermatomyositis in Guadeloupe and characterize the disease in an overseas Caribbean population. Adults meeting the 2003 ENMC diagnostic criteria who have parents or grandparents from the Caribbean and who reside in Guadeloupe will be enrolled after giving informed consent. Investigators will collect clinical, laboratory, imaging, cancer-screening, and diagnostic-timeline data to document visceral involvement and severity at diagnosis. Statistical analysis will look for demographic, ancestral, diagnostic delay, and clinical factors associated with more severe presentations to inform earlier, tailored management.
Who should consider this trial
Good fit: Adults (16 years or older) living in Guadeloupe with dermatomyositis diagnosed per the 2003 ENMC criteria who have parents or grandparents from the Caribbean, are affiliated with a social security scheme, and can provide informed consent are ideal candidates.
Not a fit: Patients who began intravenous immunoglobulins, corticosteroids, or immunosuppressants within the month before diagnosis, those under legal protection or deprived of liberty, or those not resident in Guadeloupe or without Caribbean ancestry are unlikely to be eligible or to directly benefit.
Why it matters
Potential benefit: If successful, the findings could help clinicians identify higher-risk patients earlier and tailor care to reduce complications and improve outcomes.
How similar studies have performed: This approach is largely novel for Caribbean dermatomyositis, although similar observational work has identified unusually severe phenotypes in other autoimmune diseases in overseas populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with a diagnosis of dermatomyositis according to the 2003 ENMC criteria * Patient with parents or grandparents originating from the Caribbean arc * Patient aged 16 years or older * Patient residing in Guadeloupe * Patient (or legal representative) who has received information about the study and has signed the informed consent form * Patient affiliated with a social security scheme Exclusion Criteria: * Patient who started treatment with intravenous immunoglobulins, corticosteroids, or immunosuppressants within the month prior to the diagnosis of dermatomyositis * Patient under legal protection (guardianship or trusteeship) or deprived of liberty
Where this trial is running
Pointe-à-Pitre
- CHU de la Guadeloupe — Pointe-à-Pitre, Guadeloupe (Recruiting)
Study contacts
- Principal investigator: nadège cordel, MD PhD — CHU de la Guadeloupe
- Study coordinator: melanie petapermal, Master degree
- Email: melanie.petapermal@chu-guadeloupe.fr
- Phone: +590590934667
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.